Dr. Burd has dedicated his career to researching and developing novel medical testing products, and to successfully bringing them to market. He is a founder and is currently the President & CEO of Oculir, Inc., developing a non-invasive glucose testing system for people with diabetes. In addition, Dr. Burd is CEO of ImmuneTech, makers of MyAllergyTest, a home test for allergies. Previously, Dr. Burd was a General partner of Windamere Venture Partners, a Venture Fund specializing in founding and funding healthcare companies.

While at Windamere from 1999 to 2003, he and his 2 partners founded 15 healthcare companies. These companies included MiraMedica, Inc., where Dr. Burd served as Chairman and CEO, which developed computer aided detection systems for cancer detection. Founded in 2000, MiraMedica was sold to Kodak in 2003. In addition, in 1999, Dr. Burd founded DexCom, Inc and served as President & CEO. DexCom, Inc., is developing a long-tem implantable glucose sensor for continuous glucose monitoring.

Before DexCom, Dr. Burd was the founder, President/CEO and Chairman of LXN Corporation. Dr. Burd directed the company's work to finance, develop, manufacture, and market a new diabetes self-management system. Johnson and Johnson purchased LXN in 2001. Prior to LXN, Dr. Burd held executive positions at QUIDEL Corporation, including Vice President of Research and Development, where he directed the development of products for the clinical lab, physician's office and OTC markets.

Prior to QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. Dr. Burd began his career in medical product research and development at Bayer (formerly Miles Laboratories, Inc.)

Dr. Burd has authored and co-authored numerous scientific articles and is the owner of 23 U.S. patents. He holds a Bachelor of Science Degree in Biochemistry from Purdue and earned an M.S. and Ph.D. in Biochemistry from the University of Wisconsin.